Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Suppan, C; Brcic, I; Tiran, V; Mueller, HD; Posch, F; Auer, M; Ercan, E; Ulz, P; Cote, RJ; Datar, RH; Dandachi, N; Heitzer, E; Balic, M.
Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment.
Cancers (Basel). 2019; 11(8): Doi: 10.3390/cancers11081171 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Dandachi Nadia

Heitzer Ellen

Suppan Christoph

Co-Autor*innen der Med Uni Graz

Auer Martina

Balic Marija

Brcic Iva

Ercan Erkan

Müller Hannah Deborah

Posch Florian

Tiran Verena

Ulz Peter

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

The aim of this study was to assess the prognostic and predictive value of an untargeted assessment of tumor fractions in the plasma of metastatic breast cancer patients and to compare circulating tumor DNA (ctDNA) with circulating tumor cells (CTC) and conventional tumor markers. In metastatic breast cancer patients (n = 29), tumor fractions in plasma were assessed using the untargeted mFAST-SeqS method from 127 serial blood samples. Resulting z-scores for the ctDNA were compared to tumor fractions established with the recently published ichorCNA algorithm and associated with the clinical outcome. We observed a close correlation between mFAST-SeqS z-scores and ichorCNA ctDNA quantifications. Patients with mFAST-SeqS z-scores above three (34.5%) showed significantly worse overall survival (p = 0.014) and progression-free survival (p = 0.018) compared to patients with lower values. Elevated z-score values were clearly associated with radiologically proven progression. The baseline CTC count, carcinoembryonic antigen (CEA), and cancer antigen (CA)15-5 had no prognostic impact on the outcome of patients in the analyzed cohort. This proof of principle study demonstrates the prognostic impact of ctDNA levels detected with mFAST-SeqS as a very fast and cost-effective means to assess the ctDNA fraction without prior knowledge of the genetic landscape of the tumor. Furthermore, mFAST-SeqS-based ctDNA levels provided an early means of measuring treatment response.

Find related publications in this database (Keywords)

metastatic breast cancer (MBC)

circulating tumor cells (CTCs)

cell free circulating tumor DNA (ctDNA)

mFAST-SeqS

prognosis

treatment response

© Med Uni Graz • Impressum